These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28863385)

  • 1. Tumour radiosensitivity is associated with immune activation in solid tumours.
    Strom T; Harrison LB; Giuliano AR; Schell MJ; Eschrich SA; Berglund A; Fulp W; Thapa R; Coppola D; Kim S; Frakes J; Foekens J; Mulé JJ; Torres-Roca JF
    Eur J Cancer; 2017 Oct; 84():304-314. PubMed ID: 28863385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
    Torres-Roca JF; Fulp WJ; Caudell JJ; Servant N; Bollet MA; van de Vijver M; Naghavi AO; Harris EE; Eschrich SA
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):631-8. PubMed ID: 26461005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
    Cui Y; Li B; Pollom EL; Horst KC; Li R
    Clin Cancer Res; 2018 Oct; 24(19):4754-4762. PubMed ID: 29921729
    [No Abstract]   [Full Text] [Related]  

  • 4. Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy.
    Mohammadi H; Prince A; Figura NB; Peacock JS; Fernandez DC; Montejo ME; Chon HS; Wenham RM; Eschrich SA; Torres-Roca JF; Ahmed KA
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):496-502. PubMed ID: 31759077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a radiosensitivity molecular signature in breast cancer.
    Eschrich SA; Fulp WJ; Pawitan Y; Foekens JA; Smid M; Martens JW; Echevarria M; Kamath V; Lee JH; Harris EE; Bergh J; Torres-Roca JF
    Clin Cancer Res; 2012 Sep; 18(18):5134-43. PubMed ID: 22832933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.
    Strom T; Hoffe SE; Fulp W; Frakes J; Coppola D; Springett GM; Malafa MP; Harris CL; Eschrich SA; Torres-Roca JF; Shridhar R
    Radiother Oncol; 2015 Oct; 117(1):159-64. PubMed ID: 26235848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy.
    Grass GD; Alfonso JCL; Welsh E; Ahmed KA; Teer JK; Pilon-Thomas S; Harrison LB; Cleveland JL; Mulé JJ; Eschrich SA; Enderling H; Torres-Roca JF
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):635-647. PubMed ID: 35289298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
    Jang BS; Han W; Kim IA
    Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.
    Tanić M; Krivokuća A; Čavić M; Mladenović J; Plesinac Karapandžić V; Beck S; Radulović S; Susnjar S; Janković R
    Radiat Oncol; 2018 Oct; 13(1):193. PubMed ID: 30285791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
    Hachim IY; Shams A; Lebrun JJ; Ali S
    Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The radiosensitivity index predicts for overall survival in glioblastoma.
    Ahmed KA; Chinnaiyan P; Fulp WJ; Eschrich S; Torres-Roca JF; Caudell JJ
    Oncotarget; 2015 Oct; 6(33):34414-22. PubMed ID: 26451615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
    Jang BS; Kim IA
    Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
    Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
    Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
    Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
    Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow.
    Kunkler IH; Ward C; Langdon SP
    Breast; 2015 Nov; 24 Suppl 2():S114-9. PubMed ID: 26429399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Scott JG; Berglund A; Schell MJ; Mihaylov I; Fulp WJ; Yue B; Welsh E; Caudell JJ; Ahmed K; Strom TS; Mellon E; Venkat P; Johnstone P; Foekens J; Lee J; Moros E; Dalton WS; Eschrich SA; McLeod H; Harrison LB; Torres-Roca JF
    Lancet Oncol; 2017 Feb; 18(2):202-211. PubMed ID: 27993569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
    Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.